Abstracts A95 NICE fi rst. Nineteen of the 46 submissions were appraised by NICE; 10% of the cases were fi rst assessed by NICE, 60% were appraised by NICE second, and in 30% of the cases, NICE were the last in the sequence to appraise. It is interesting to note that the rate of acceptance by the SMC was approximately 65% regardless of whether the intervention was appraised by the SMC or CADTH fi rst. In contrast the acceptance rate for CADTH was observed to be much higher when interventions were appraised by the SMC fi rst compared to when CADTH conducted the fi rst appraisal; 56% and 20% respectively. CONCLUSIONS: The SMC have generally received submissions before NICE and CADTH. In comparison, NICE were rarely the fi rst to appraise an intervention. Reviewing the sequence in which submissions are appraised by each of these bodies and the infl uence of this on the guidance issued may inform future strategic planning of submissions.
PHP89 APPLES AND ORANGES? COMPARATIVE EFFECTIVENESS IN THE UNITED STATES AND OTHER COUNTRIES
Levy AR y 1 , Johnston KM 2 , Mitton C 3 , Risebrough N 1 , Harrigan B 1 , Briggs A 4 1 Oxford Outcomes Ltd, Vancouver, BC, Canada, 2 University of British Columbia, Vancouver, BC, Canada, 3 University of British Columbia Okanagan, Kelowna, BC, Canada, 4 University of Glasgow, Glasgow, UK OBJECTIVES: Health technology assessment (HTA) started in the United States (US) to quantify the benefi ts, harms and costs associated with new technologies. Paralleling methodological advances, applied HTA processes were instituted in many countries to inform decisions about adopting new technologies. Within the context of discussions regarding a new center for comparative effectiveness in the US, we compared HTA of medications in six jurisdictions: Australia, Canada, England and Wales, the Netherlands, Scotland and Sweden. The objective was to identify characteristics of HTA processes and agencies that may inform the structure and operation of a US center for comparative effectiveness. METHODS: We identifi ed characteristics of each health care system and HTA processes, including: the medications reimbursement processes; whether recommendations are mandatory; and structure and transparency of the process using the accountability for reasonableness framework. RESULTS: For Australia, England and Wales and the Netherlands, reimbursement decisions are made nationally, while in Canada, Scotland, and Sweden, formularies are maintained regionally. HTA processes range from manufacturer-prepared single product submissions to comprehensive assessments based on de novo analyses. While six jurisdictions have quasi-governmental HTA agencies, the Netherlands relies largely on a reference-pricing system. Sweden has two HTA agencies: one for rapid assessment of single medications and another which undertakes multiple-technology assessments involving other funding silos. Scotland, and to lesser extents England and Wales and Sweden, have implemented transparent processes, e.g., by posting meeting minutes and the reasoning for recommendations. CONCLUSIONS: The US health care system is fragmented and characterized by insured populations with different health needs. Characteristics directly relevant to a US centre include having: nonmandatory recommendations; and transparent two-tiered processes. Collecting better evidence on real-world treatment effects -as is being done in some jurisdictionswould increase the number and types of stakeholders who could apply the information for decision-making.
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PHP90 THE IMPACT OF AN ELECTRONIC PRESCRIBING SOLUTION ON THE SELECTION AND PRESCRIBING OF COST-EFFECTIVE THERAPEUTIC OPTIONS
Hutchins DS 1 , Liberman JN 2 , Berger JE 3 , Jan SA 4 , Johnson MM 4 1 CVS Caremark Corporation, Scottsdale, AZ, USA, 2 CVS Caremark Corporation, Hunt Valley, MD, USA, 3 CVS Caremark Corporation, Northbrook, IL, USA, 4 Horizon Blue Cross Blue Shield of New Jersey, Newark, NJ, USA OBJECTIVES: To assess the impact electronic prescribing system the use of an has on a provider's prescribing of low cost generic drugs through lower costing channels. METHODS: Generic/brand, mail/retail, and cost-per-day (costs) for over nine million adjudicated prescriptions dispensed between July 2002 and December 2005 were incorporated into independent multivariate logistic and general linear models to compare prescriptions from 468 providers prescribed before and after using an electronic prescribing system and 28,734 "no use" (control) providers. Separate models for ACE Inhibitors, ARB and ARB Combinations, H2 Antagonists, HMG Inhibitors, NSAIDs, PPIs, and SSRIs classes included independent variables for: provider degree, specialty, and electronic prescribing system use (no, little and regular use prescribed 50 prescriptions/month); patient sex, age (continuous), and regimen status; claim month and distribution channel (except in mail/retail models). Signifi cance was a p-value 0.01. RESULTS: Generic and mail prescriptions were generally more likely to be prescribed from providers with regular use (ORs: 0.80 C1.20) and less likely from those with little or no use (ORs: 0.65 C1.23) than prescriptions from the preperiod of providers who became regular users (OR 1.00), with most signifi cant and few exceptions. Costs were generally lower for providers with regular use (CEs: $ 0.33 C$0.04) and higher for providers with little or no use (CEs: $ 0.13 C$0.14) than prescriptions from the pre-period of providers who became regular users (CE $0.00), with some signifi cant and some exceptions. CONCLUSIONS: Similar underlying patterns found across multiple classes provide support for linking regular use of electronic prescribing systems to providers being even more likely to prescribe generics drugs and having them dispensed through mail, both of which likely lower overall costs. Additional research should be performed to better assess the robustness of these fi nding as participation expands and in more therapeutic classes.
PHP91
MEDICARE PART D'S EFFECT ON PRESCRIBING VOLUME: AVERAGE MONTHLY UTILIZATION OF SELECTED HIGH USE DRUGS IN THE PROTECTED CLASSES BY DIFFERENT SPECIALTIES
White C 1 , Sepulveda B 2 , Doyle JJ 3 1 Quintiles Consulting, Hawthorne, NY, USA, 2 Global Market Access, Quintiles Consulting, Hawthorne, NY, USA, 3 Quintiles Global Consulting, Hawthorne, NY, USA OBJECTIVES: To determine whether the implementation of Medicare Part D coverage affected trends in average per physician prescription volume of select drugs in the six classes deemed by CMS/Medicare Part D to be medically necessary for reimbursement. To assess these trends over the 2005-2008 period, including the January 1, 2006 implementation of Medicare Part D. To investigate whether prescribers of different specialties were affected to a greater of lesser extent than their peers. METHODS: For each of the six protected classes defi ned by CMS (Antineoplastics, Antidepressants, Anticonvulsants, Immunosuppressants, Antipsychotics, Antiretrovirals) a comparative market basket consisting of the top 2 prescribed anticonvulsants (clonazepam, gabapentin), antidepressants (escitaprolam, fl uoxetine), antipsychotics (quetiapine, risperidone), HIV/AIDS (emtricitabine/tenofovir, ritonavir) and immunosuppressants (azathioprine, mycophenolate) were selected based on total prescriptions (TRx) between January 2005 and June 2008. For that time frame, average prescription volume, by individual physician, were collected monthly using SDI/ Verispan's VONA and VOPA databases. RESULTS: Of 103 physician specialty/molecule prescribing pairs, average monthly prescription volume for the 12 month period after implementation of Medicare Part D (January 2006 -December 2006) coverage increased significantly (p 0.05) versus the prior 12 months (January 2005-December 2005 for 79% (34/43) of combinations examined, and conversely, a signifi cant (p 0.05) decrease was observed for 80% (48/60) combinations. CONCLUSIONS: The introduction of Medicare Part D had signifi cant impact on utilization for the majority of high volume drugs in the Medicare Part D designated protected classes. A possible explanation is that the reorganization of formulary structures and tier placement for many of these drugs led to pricing changes for patients, which in turn were observed by physicians and led to subtle but signifi cant changes in prescribing behavior. In addition to changes for specialty physicians, signifi cant changes in volume were also noted for GP/FP/IM physicians. Ongoing investigation into drug pricing and tier placement may lead to greater clarity.
